Semaglutide in Overweight and Obese patients: Cardiovascular and/or Renal Metabolic Benefits

• Главные авторы: Jorge Rico-Fontalvo (Автор), Rodrigo Daza-Arnedo (Автор), Jose Cabrales (Автор), Juan Diego Montejo-Hernández (Автор)
• Формат: ‌
• Опубликовано: Asociación Colombiana de Nefrología e Hipertensión Arterial, 2022-10-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

We have read the article published by Kadowaki, et al. 1 "Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes mellitus in an East Asian population (STEP 6): A randomized, double blind, double dummy, placebo controlled, phase 3a trial", where the au...